- Home
- CYCU vs PHGE Comparison
CYCU vs PHGE Comparison
Compare CYCU & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCU
- PHGE
- Stock Information
- Founded
- CYCU N/A
- PHGE 2015
- Country
- CYCU United States
- PHGE Israel
- Employees
- CYCU N/A
- PHGE N/A
- Industry
- CYCU
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- CYCU
- PHGE Health Care
- Exchange
- CYCU Nasdaq
- PHGE Nasdaq
- Market Cap
- CYCU 13.1M
- PHGE 11.0M
- IPO Year
- CYCU N/A
- PHGE N/A
- Fundamental
- Price
- CYCU $0.37
- PHGE $0.46
- Analyst Decision
- CYCU
- PHGE Strong Buy
- Analyst Count
- CYCU 0
- PHGE 1
- Target Price
- CYCU N/A
- PHGE $15.00
- AVG Volume (30 Days)
- CYCU 1.8M
- PHGE 271.1K
- Earning Date
- CYCU 06-06-2025
- PHGE 08-13-2025
- Dividend Yield
- CYCU N/A
- PHGE N/A
- EPS Growth
- CYCU N/A
- PHGE N/A
- EPS
- CYCU N/A
- PHGE N/A
- Revenue
- CYCU $17,398,680.00
- PHGE N/A
- Revenue This Year
- CYCU N/A
- PHGE N/A
- Revenue Next Year
- CYCU N/A
- PHGE N/A
- P/E Ratio
- CYCU N/A
- PHGE N/A
- Revenue Growth
- CYCU N/A
- PHGE N/A
- 52 Week Low
- CYCU $0.26
- PHGE $0.34
- 52 Week High
- CYCU $10.99
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- CYCU N/A
- PHGE 44.42
- Support Level
- CYCU N/A
- PHGE $0.45
- Resistance Level
- CYCU N/A
- PHGE $0.51
- Average True Range (ATR)
- CYCU 0.00
- PHGE 0.05
- MACD
- CYCU 0.00
- PHGE 0.01
- Stochastic Oscillator
- CYCU 0.00
- PHGE 55.56
About CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).